Randomized clinical trials (RCTs) for the prevention of vascular events in patients with coronary artery disease (CAD) over the past decade have clearly demonstrated that colchicine is able to reduce the composite endpoint of myocardial infarction, ischemic stroke, need for urgent coronary revascularization and cardiovascular death [1,2]. The new European[3] and North American [4] guidelines on chronic and acute coronary syndromes respectively, recommend a low dose of colchicine in addition to standard therapies for the prevention of vascular events.
